The document describes the EpiTect Methyl II PCR Array System for analyzing DNA methylation. It provides an overview of the system which enables pathway or disease-focused profiling of regional DNA methylation using optimized kits, assays, and data analysis templates. The system offers a complete solution for DNA methylation analysis from sample isolation through data analysis. Key advantages include its ability to simultaneously analyze methylation of many genes, compatibility with standard qPCR instruments, and generation of results comparable to bisulfite sequencing but with higher throughput and without the need for bisulfite conversion.
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
This presentation (in English) made at ONCOTRANS in Besançon on Friday 3rd 2017 reviews the potential for TGF-beta inhibition in hepatocellular carcinoma based on preclinical and clinical data.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
CTC Detection and Molecular Characterization – Challenges and SolutionsQIAGEN
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and profiling CTCs from blood samples is very challenging. In this webinar, Dr. Siegfried Hauch will introduce the well-known AdnaTests, which uses the Combination of Combinations Principle (COCP) to enable enriching and detecting CTCs in whole blood with high specificity and sensitivity, and how to overcome challenges in CTC enrichment and detection. The AdnaTests combine an immunomagnetic capturing method that increases purity, and is followed by molecular profiling of the captured CTCs. In addition, leukocyte contamination is another issue in CTCs detection and may lead to false positive results due to illegitimate expression of target genes or false interpretation. The AdnaWash is developed to reduce leukocyte contamination to such a level that whole gene panels can be analyzed while maintaining the required specificity and sensitivity.
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
This presentation (in English) made at ONCOTRANS in Besançon on Friday 3rd 2017 reviews the potential for TGF-beta inhibition in hepatocellular carcinoma based on preclinical and clinical data.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
CTC Detection and Molecular Characterization – Challenges and SolutionsQIAGEN
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and profiling CTCs from blood samples is very challenging. In this webinar, Dr. Siegfried Hauch will introduce the well-known AdnaTests, which uses the Combination of Combinations Principle (COCP) to enable enriching and detecting CTCs in whole blood with high specificity and sensitivity, and how to overcome challenges in CTC enrichment and detection. The AdnaTests combine an immunomagnetic capturing method that increases purity, and is followed by molecular profiling of the captured CTCs. In addition, leukocyte contamination is another issue in CTCs detection and may lead to false positive results due to illegitimate expression of target genes or false interpretation. The AdnaWash is developed to reduce leukocyte contamination to such a level that whole gene panels can be analyzed while maintaining the required specificity and sensitivity.
New Technology and Workflow for Integrated Collection, Stabilization and Puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Detection and quantification of mutant alleles in tumor tissue allow for research disease monitoring and the research of drug efficacy. Detection of emerging secondary mutations in the same tumor tissue causing resistance to potential treatment will help guide decisions on future treatment plans. Testing for the presence of mutations in cell free DNA (cfDNA) is a less invasive research method than using tumor tissue. We created a research tool for mutation detection at a sensitivity level of 1% and below. This allows researchers to find correlation between types of mutations and types of tumors and determination of potential secondary mutations.
The tool combines TaqMan® SNP Genotyping Assays with digital PCR. A set of assays was optimized for use
in digital PCR with the QuantStudio® 3D Digital PCR System. In digital PCR, partitioning the sample into many individual reaction wells facilitates detection and quantification of rare mutant alleles. TaqMan® SNP Genotyping Assays ensure reliable discrimination of mutant and wild-type allele. Our current set of 60 assays covers mutations commonly found in tumor tissues, such as: BRAF V600E, mutations in EGFR exons 19, 20 and 21, KRAS codons 12 and 13, PIK3CA exons 9 and 20, and the JAK2 V617F mutations. All assays were wet-lab tested at a 10% mutation rate and a 1% mutation rate using mutant plasmid spiked into wild-type genomic DNA. Additionally, selected assays were tested at the 0.1% mutation rate using mutant cell lines spiked into wild-type genomic DNA. Wet-lab results confirm that all assays showed superior performance discriminating mutant and wild-type alleles. Mutant alleles were successfully detected as low as 0.1%.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...QIAGEN
Meningioma’s display a broad spectrum of clinical, histological and cytogenetic features even within the same WHO grade often posing a challenge for classification and prognostic stratification. In this webinar, we will describe our experience of using targeted amplicon sequencing to develop rapid clinical sequencing system to identify and confirm the meningioma genotype in just two weeks. In addition the details of the three meningioma categories and the genes involved will be discussed.
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
New technology and workflow for integrated collection, stabilization and puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphonyPAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this slidedeck, this new technology development is presented in comparison to other existing technologies.
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...QIAGEN
This slidedeck focuses on the design of a large cohort study for assessing breast cancer risk and how an innovative digital sequencing approach is able to solve the previously unmet challenges of this type of NGS study design. Our speaker, Dr. Fergus J. Couch of the Mayo Clinic, presents on the design of this NCI-funded project, which comprises the sequencing of 60,000 samples to assess the risk of breast cancer through association with targeted genes. The design and size of the study requires an accurate, robust and high-throughput sequencing method. The investigators are using a digital DNA sequencing approach from QIAGEN that incorporates molecular barcodes to tag and remove PCR duplicates and increase NGS assay sensitivity. The approach also uses proprietary chemistry that enables uniform sequencing to efficiently utilize sequencing power and deliver optimized results.
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel...Qiagen - Egypt
Would you like to measure signaling pathway activity in your favorite cell? Learn how to successfully apply convenient and robust reporter assays to your RNA interference, gene over-expression, protein, or small molecule studies. The Cignal Reporter Assays are an excellent tool for studying pathway signaling activity in cells that are amenable to transfection, available for studying numerous pathways including (ROS, Wnt, NF-kB, Notch, cAMP/PKA, TGFbeta, and the Cignal Lenti Reporter Assays combines the power of a lentiviral delivery system with our robust transcription factor reporter technology, enabling you to study signal pathways in virtually any cell type. You can find a technology overview, protocol tutorial, and application examples in the following presentation.
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...QIAGEN
Would you like to measure signaling pathway activity in your favorite cell? Learn how to successfully apply convenient and robust reporter assays to your RNA interference, gene over-expression, protein, or small molecule studies. The Cignal Reporter Assays are an excellent tool for studying pathway signaling activity in cells that are amenable to transfection, available for studying numerous pathways including (ROS, Wnt, NF-kB, Notch, cAMP/PKA, TGFbeta, and the Cignal Lenti Reporter Assays combines the power of a lentiviral delivery system with our robust transcription factor reporter technology, enabling you to study signal pathways in virtually any cell type. You can find a technology overview, protocol tutorial, and application examples in the following presentation.
Circulating cell free DNA is a potential tumor marker in a non-invasive blood test for the treatment and evaluation of cancer and recurrence monitoring. As circulating tumor DNA is often present at low frequencies within circulating cell free DNA, targeted sequencing on the Ion Torrent™ platform is an optimal tool or mutation detection with very little sample input required. Here, we demonstrate a complete workflow from isolation through molecular characterization of circulating tumor DNA. We have optimized a protocol using magnetic beads to isolate circulating cell free DNA. This protocol is easily automated to process up to 192 samples a day. It is also easily scalable for any input volume and can elute in volumes down to 15 μL resulting in no loss of low frequency alleles. We demonstrate comparable performance between this bead based isolation and column based isolation. We have completed molecular characterization of circulating cell free DNA using the multiplexing capabilities of AmpliSeq™ and the Ion PGM™. With the Ion AmpliSeq™ Cancer Hotspot Panel v2, we performed targeted sequencing of 50 genes of interest, covering 2800 COSMIC mutations. We demonstrate good reproducibility of amplicon representation as well as allelic frequencies. Through saturation studies and subsampling, we have determined the limit of detection of hotspots circulating cell free DNA on the Ion PGM™ to be below 1%. We further demonstrate proof of principle of this workflow on circulating cell free DNA and matched FFPE samples. Our results verify the accuracy and ease of our workflow. This protocol, from isolation through targeted sequencing, will not only result in a simple sample preparation for circulating cell free DNA but also facilitate rapid mutation detection to advance cancer research.
NGS for Infectious Disease Diagnostics: An Opportunity for Growth Alira Health
Infectious diseases are a major public health concern causing over 3.5 million deaths worldwide. Diagnosing patients as quickly and effectively as possible is crucial for managing disease outbreaks. Next-generation sequencing (NGS) provides unique capabilities to understand the genetic profile of infectious disease patients that no other technology can match.
Whole-genome metagenomics allows clinicians to take a deeper dive into pathogens by generating big-data about their characteristics. This data can be rapidly analyzed using complex bioinformatics software algorithms to achieve clinical-grade diagnostic accuracy. In a healthcare system shifting towards personalized medicine, NGS can provide clinicians the tools that they need to prescribe individualized treatments to save patients who were previously untreatable. The result is improved quality of care, better treatment regimes, and cost-saving healthcare.
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3ryE5ST
Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions.
Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access.
The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures.
In this webinar, you will:
• Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells
• Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms.
• Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks
Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...QIAGEN
Circulating miRNAs have great potential as biomarkers due to their aberrant expression in cancer and other diseases. However, miRNAs from body fluids are hard to obtain in amounts sufficient for detailed miRNome profiling. This slideshow describes an integrated, PCR-based system that reduces the amount of sample required for full miRNome profiling by several orders of magnitude and provides unparalleled reproducibility and precision. Detailed protocols are highlighted regarding RNA isolation, real-time quantification and data analysis for the assessment of serum, plasma, urine and cerebrospinal fluid samples. This system enables accurate miRNA analysis on the smallest of samples and opens up new possibilities for biomarker development.
Setting up for successful lot release testing by Edmund AngMilliporeSigma
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Does your cell line have a secret? Avoid surprises with characterizationMerck Life Sciences
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
miRNA profiling from blood challenges and recommendations - Download the articleQIAGEN
The discovery of stable miRNA species circulating in blood has led to increased research focus on disease-related variations in serum and plasma miRNA expression and the possibility that such variations could serve as noninvasive biomarkers for disease. Working with serum and plasma miRNA presents various challenges in purification and characterization. In this paper, we outline QIAGEN recommendations for robust purification and quantification, as well as reliable data normalization and analysis.
New Technology and Workflow for Integrated Collection, Stabilization and Puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene® Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphony® PAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development is presented in comparison to other existing technologies.
Detection and quantification of mutant alleles in tumor tissue allow for research disease monitoring and the research of drug efficacy. Detection of emerging secondary mutations in the same tumor tissue causing resistance to potential treatment will help guide decisions on future treatment plans. Testing for the presence of mutations in cell free DNA (cfDNA) is a less invasive research method than using tumor tissue. We created a research tool for mutation detection at a sensitivity level of 1% and below. This allows researchers to find correlation between types of mutations and types of tumors and determination of potential secondary mutations.
The tool combines TaqMan® SNP Genotyping Assays with digital PCR. A set of assays was optimized for use
in digital PCR with the QuantStudio® 3D Digital PCR System. In digital PCR, partitioning the sample into many individual reaction wells facilitates detection and quantification of rare mutant alleles. TaqMan® SNP Genotyping Assays ensure reliable discrimination of mutant and wild-type allele. Our current set of 60 assays covers mutations commonly found in tumor tissues, such as: BRAF V600E, mutations in EGFR exons 19, 20 and 21, KRAS codons 12 and 13, PIK3CA exons 9 and 20, and the JAK2 V617F mutations. All assays were wet-lab tested at a 10% mutation rate and a 1% mutation rate using mutant plasmid spiked into wild-type genomic DNA. Additionally, selected assays were tested at the 0.1% mutation rate using mutant cell lines spiked into wild-type genomic DNA. Wet-lab results confirm that all assays showed superior performance discriminating mutant and wild-type alleles. Mutant alleles were successfully detected as low as 0.1%.
Breaking the Status Quo: Using Mass Spectrometry to detect Host Cell ProteinsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3b3Tbcd
Measurement of host cell proteins is vital to ensuring a biotherapy's purity and a patient's safety. Biotherapies treat diseases with products produced by living organisms, as a result, host cell components must be characterized and controlled. We'll review new methods within product characterization for detection.
Trace amounts of host cell proteins can be present after the production and purification of any biopharmaceutical. Detection of these species requires highly specific techniques to accurately quantify even low levels of contamination. Host cell protein impurities, present at PPM-levels in biotherapies, are a major immunogenicity risk because they can elicit an unpredictable immune response in patients. Their complex and diverse nature makes them challenging to detect or monitor. With acceptance criteria for host residual DNA usually set at a very low level (often =1.0 pg of DNA per mg of drug substance), effective removal techniques and sensitive methods of detection are critical.
Antibody-based techniques, like the enzyme-linked immunosorbent assay (ELISA), have been used to assess the HCP load of biotherapeutics before and after process changes. However, these techniques do not necessarily detect qualitative changes in the HCP population. In this webinar, we will discuss how mass spectrometry (MS)-based approaches coupled with ELISA methods help detect qualitative and quantitative differences in HCP populations.
In this webinar, you will learn:
• Comprehensive HCP ID and semi-quantitation
• HC agnostic process
• Creation of process specific database
• Differential clearance of specific HCPs throughout purification steps
• Monitoring of problematic species e.g. immunogenic (PLBL2), lipases and proteases
• Explanation about why 90% of BLAs filed included this HCP MS data
Developing a Rapid Clinical Sequencing System to Classify Meningioma: Meet th...QIAGEN
Meningioma’s display a broad spectrum of clinical, histological and cytogenetic features even within the same WHO grade often posing a challenge for classification and prognostic stratification. In this webinar, we will describe our experience of using targeted amplicon sequencing to develop rapid clinical sequencing system to identify and confirm the meningioma genotype in just two weeks. In addition the details of the three meningioma categories and the genes involved will be discussed.
Releasing Your AAV Therapy with Confidence: Regulatory Considerations and Key...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3icKkbZ
Ensuring the safety and quality of your AAV vector is of the utmost importance. Join this webinar for a high-level overview of the regulatory requirements for AAV testing throughout the manufacturing process, as well as a more detailed look at rcAAV and infectious titer assays.
Adeno-associated virus (AAV) vectors possess a number of advantages for use in human therapy including: high titer preparations, low immunogenicity, capacity to infect a wide range of cell types, and replication deficiency. Even with these advantages, there are biosafety concerns to consider when using AAV vectors.
This webinar will discuss key regulatory considerations across the manufacturing process, from the helper/packaging plasmids through to lot release testing. We will highlight critical assays that are required and delve into specifics on replication competent AAV testing and infectious titer determination by TCID50.
In this webinar, you will learn:
• Critical biosafety considerations for AAV vectors based on the latest regulatory guidance
• How replication competent AAV testing fits into your bulk and final release testing package
• The benefits of routine and platform assays over custom assay development
Presented by:
Steven McDade, Senior Technical Specialist, Field Technology Management
Alfonso Lavorgna, Ph.D., Operations Manager, Virology Services
New technology and workflow for integrated collection, stabilization and puri...QIAGEN
Research into non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing based on circulating cell-free DNA (ccfDNA) is rapidly expanding. However, detection and quantification of ccfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport. PreAnalytiX has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube, a plastic blood collection tube with a unique, non-crosslinking chemistry that preserves extracellular levels of ccfDNA and prevents the release of intracellular DNA from cells into the plasma, and the QIAsymphonyPAXgene Blood ccfDNA Kit for automated ccfDNA extraction from up to 5 ml of plasma. In this slidedeck, this new technology development is presented in comparison to other existing technologies.
Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer...QIAGEN
This slidedeck focuses on the design of a large cohort study for assessing breast cancer risk and how an innovative digital sequencing approach is able to solve the previously unmet challenges of this type of NGS study design. Our speaker, Dr. Fergus J. Couch of the Mayo Clinic, presents on the design of this NCI-funded project, which comprises the sequencing of 60,000 samples to assess the risk of breast cancer through association with targeted genes. The design and size of the study requires an accurate, robust and high-throughput sequencing method. The investigators are using a digital DNA sequencing approach from QIAGEN that incorporates molecular barcodes to tag and remove PCR duplicates and increase NGS assay sensitivity. The approach also uses proprietary chemistry that enables uniform sequencing to efficiently utilize sequencing power and deliver optimized results.
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cel...Qiagen - Egypt
Would you like to measure signaling pathway activity in your favorite cell? Learn how to successfully apply convenient and robust reporter assays to your RNA interference, gene over-expression, protein, or small molecule studies. The Cignal Reporter Assays are an excellent tool for studying pathway signaling activity in cells that are amenable to transfection, available for studying numerous pathways including (ROS, Wnt, NF-kB, Notch, cAMP/PKA, TGFbeta, and the Cignal Lenti Reporter Assays combines the power of a lentiviral delivery system with our robust transcription factor reporter technology, enabling you to study signal pathways in virtually any cell type. You can find a technology overview, protocol tutorial, and application examples in the following presentation.
Cell-based Reporter Assays: Measure 45 Signaling Pathway Activity in Any Cell...QIAGEN
Would you like to measure signaling pathway activity in your favorite cell? Learn how to successfully apply convenient and robust reporter assays to your RNA interference, gene over-expression, protein, or small molecule studies. The Cignal Reporter Assays are an excellent tool for studying pathway signaling activity in cells that are amenable to transfection, available for studying numerous pathways including (ROS, Wnt, NF-kB, Notch, cAMP/PKA, TGFbeta, and the Cignal Lenti Reporter Assays combines the power of a lentiviral delivery system with our robust transcription factor reporter technology, enabling you to study signal pathways in virtually any cell type. You can find a technology overview, protocol tutorial, and application examples in the following presentation.
Circulating cell free DNA is a potential tumor marker in a non-invasive blood test for the treatment and evaluation of cancer and recurrence monitoring. As circulating tumor DNA is often present at low frequencies within circulating cell free DNA, targeted sequencing on the Ion Torrent™ platform is an optimal tool or mutation detection with very little sample input required. Here, we demonstrate a complete workflow from isolation through molecular characterization of circulating tumor DNA. We have optimized a protocol using magnetic beads to isolate circulating cell free DNA. This protocol is easily automated to process up to 192 samples a day. It is also easily scalable for any input volume and can elute in volumes down to 15 μL resulting in no loss of low frequency alleles. We demonstrate comparable performance between this bead based isolation and column based isolation. We have completed molecular characterization of circulating cell free DNA using the multiplexing capabilities of AmpliSeq™ and the Ion PGM™. With the Ion AmpliSeq™ Cancer Hotspot Panel v2, we performed targeted sequencing of 50 genes of interest, covering 2800 COSMIC mutations. We demonstrate good reproducibility of amplicon representation as well as allelic frequencies. Through saturation studies and subsampling, we have determined the limit of detection of hotspots circulating cell free DNA on the Ion PGM™ to be below 1%. We further demonstrate proof of principle of this workflow on circulating cell free DNA and matched FFPE samples. Our results verify the accuracy and ease of our workflow. This protocol, from isolation through targeted sequencing, will not only result in a simple sample preparation for circulating cell free DNA but also facilitate rapid mutation detection to advance cancer research.
NGS for Infectious Disease Diagnostics: An Opportunity for Growth Alira Health
Infectious diseases are a major public health concern causing over 3.5 million deaths worldwide. Diagnosing patients as quickly and effectively as possible is crucial for managing disease outbreaks. Next-generation sequencing (NGS) provides unique capabilities to understand the genetic profile of infectious disease patients that no other technology can match.
Whole-genome metagenomics allows clinicians to take a deeper dive into pathogens by generating big-data about their characteristics. This data can be rapidly analyzed using complex bioinformatics software algorithms to achieve clinical-grade diagnostic accuracy. In a healthcare system shifting towards personalized medicine, NGS can provide clinicians the tools that they need to prescribe individualized treatments to save patients who were previously untreatable. The result is improved quality of care, better treatment regimes, and cost-saving healthcare.
Achieving High Yields in Scalable Xeno Free Culture Formats with Mesenchymal ...Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3ryE5ST
Optimize your mesenchymal stem cell growth. Join our webinar to learn more about our GMP-compliant xeno free media formulation that supports high performance expansions and compatibility with scalable xeno free manufacturing conditions.
Optimizing ex vivo cell expansion processes in preparation for clinical use is a critical step in cell therapy manufacturing. Given the curative and lifesaving impacts these therapies can have on patients, overcoming roadblocks with scalability and supply chain, using high quality raw materials are essential for therapeutic access.
The GMP-compliant Stemline® XF MSC Medium and cocktail promotes expansion of human mesenchymal stromal/stem cells (hMSCs) to high densities while maintaining cell identity and quality. This product was designed for derivation and expansion of MSCs using xeno free conditions in planar and microcarrier-based culture platforms, easing the transfer between research, clinical, and manufacturing scale cultures.
In this webinar, you will:
• Explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells
• Discover ways to derive MSC's from Bone Marrow in Xeno Free conditions from static to microcarrier-based suspension culture platforms.
• Learn how Stemline® XF MSC Media provides robust performance and reduces scalability roadblocks
Presented by: Kathleen Ongena, Ph.D., Head of Customer Applications and Mark Ventresco, Cell Therapy Product Manager
Biofluid miRNA profiling: from sample to biomarker: miRNA and its Role in Hum...QIAGEN
Circulating miRNAs have great potential as biomarkers due to their aberrant expression in cancer and other diseases. However, miRNAs from body fluids are hard to obtain in amounts sufficient for detailed miRNome profiling. This slideshow describes an integrated, PCR-based system that reduces the amount of sample required for full miRNome profiling by several orders of magnitude and provides unparalleled reproducibility and precision. Detailed protocols are highlighted regarding RNA isolation, real-time quantification and data analysis for the assessment of serum, plasma, urine and cerebrospinal fluid samples. This system enables accurate miRNA analysis on the smallest of samples and opens up new possibilities for biomarker development.
Setting up for successful lot release testing by Edmund AngMilliporeSigma
Is your lot release testing strategy ready for global commercialization?
In this webinar, you will learn:
• CMC testing requirements with CHO production platform for global commercialization
• Lot release testing of product intermediates and final product
• Product-specific qualification study
• Alternative rapid testing methods to advance lot release testing
CHO cells continue to serve as a key cell substrate for the manufacturing of recombinant proteins that span beyond therapeutic monoclonal antibodies and including subunit vaccines.
In this presentation, we will cover the CMC testing requirements with CHO production platform for global commercialization, Lot release testing of product intermediates and final product, product-specific qualification study and highlight the application of new testing methods and the benefits they bring to advance Lot Release Testing.
Does your cell line have a secret? Avoid surprises with characterizationMerck Life Sciences
Watch the recording of this webinar here: https://bit.ly/2Y05bV4
The first step to avoiding an unpleasant and costly contamination event is characterization of your cell banks.
Regardless of the biotech product, careful characterization of the cell banks used in its production is the first step in mitigating the risk of a contamination event. In fact, cell line characterization is an important component of the overall viral safety strategy for the product. We will describe the testing necessary to ensure cell banks are free from infectious and other adverse agents and that meets current regulatory expectations. Different levels of testing are performed for master, working, and end of production cell banks, and the differences in testing for each of these types of banks will be discussed.
In this webinar, you will learn:
• The types of tests that are needed to fully characterize your cell banks
• The best tests to use for your particular cell line
• Reasons why a viral contaminant may be missed
miRNA profiling from blood challenges and recommendations - Download the articleQIAGEN
The discovery of stable miRNA species circulating in blood has led to increased research focus on disease-related variations in serum and plasma miRNA expression and the possibility that such variations could serve as noninvasive biomarkers for disease. Working with serum and plasma miRNA presents various challenges in purification and characterization. In this paper, we outline QIAGEN recommendations for robust purification and quantification, as well as reliable data normalization and analysis.
Please note: This presentation accompanies a recorded webinar at:
https://www1.gotomeeting.com/register/347794241
Biomarkers for studying gene regulation and cell function can be efficiently analyzed by multiplexed methods. Dr. Jim Lazar from OriGene Technologies will provide an overview of four different but related detection technologies that can be used to analyze genetic variants, microRNA expression, transcription factor binding, and protein expression on the Luminex xMAP platform. OriGene’s broad panel of assays and tools for discovery, analysis and validation of multiple classes of important biomarkers will allow researcher to develop more accurate descriptions of biologically complex systems.
Total RNA Discovery for RNA Biomarker Development WebinarQIAGEN
Precision medicine offers to transform patient care by targeting treatment to those with most to gain. To date the most significant advances have been at the level of DNA, for example, the use of somatic DNA alterations as diagnostic indicators of disease and for prediction of pharmacodynamic response. Development of RNA expression signatures as biomarkers has been more problematic. While RNA expression analysis has yielded valuable insights into the biological mechanisms of disease, RNA is a more unstable molecule than DNA, and more easily damaged or degraded during sample collection and isolation. In addition, RNA levels are inherently dynamic and gene expression signatures are extraordinarily complex. Recently, much progress has been made in identifying key changes in gene expression in cancer and other diseases, as well as identifying expression signatures in circulating nucleic acid that have the potential to be developed into diagnostic and prognostic indicators.
Robert Anders, MD, PhD, Julie R. Brahmer, MD, MSc, and Christopher D. Gocke, MD, prepared useful Practice Aids pertaining to immunotherapy and biomarker testing for this CME/MOC/CC activity titled "Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era." For the full presentation, monograph, complete CME/MOC/CC information, and to apply for credit, please visit us at http://bit.ly/2L7zlSy. CME/MOC/CC credit will be available until May 2, 2020.
Clinical molecular diagnostics for drug guidanceNikesh Shah
1. Be familiar with next generation molecular diagnostic techniques that can provide guidance in clinical decision making
2. Identify the utility of these diagnostic approaches with some examples
3. Be aware of the challenges that exist in implementing these tools as part of the routine clinical decision making process, especially in resource limited settings
1. EpiTect Methyl II PCR Array System
Samuel J. Rulli, Jr., Ph. D.
Epigenetics Applications Scientist
Samuel.Rulli@QIAGEN.com
QIAwebinars@QIAGEN.com
The EpiTect Methyl qPCR Arrays and Assays are intended for molecular biology applications.
This product is not intended for diagnosis, prevention, or treatment of disease.
1
Sample & Assay Technologies
2. EpiTect Methyl II PCR Array System
Questions, Comments, Concerns?
US Applications Support
888-503-3187
support@sabiosciences.com
̣
Questions, Comments, Concerns?
Global Applications Support
SAB.EU@qiagen.com
The EpiTect Methyl II PCR Arrays and Assays are intended for molecular biology applications.
This product is not intended for diagnosis, prevention, or treatment of disease.
2
Sample & Assay Technologies
3. Disclaimer and intended use
EpiTect Methyl II PCR Array product line
EpiTect® Kits are intended for molecular biology
applications. These products are not intended
for the diagnosis, prevention, or treatment of a
disease.
The EpiTect Methyl II qPCR system enables
pathway or disease-focused profiling of regional
DNA methylation using MethylScreen™
technology provided under license from Orion
Genomics, LLC.
For up-to-date licensing information and productspecific disclaimers, see the respective QIAGEN
kit handbook or user manual. QIAGEN kit
handbooks and user manuals are available at
www.qiagen.com or can be requested from
QIAGEN Technical Services or your local
distributor.
̣
3
Sample & Assay Technologies
4. Topics for Discussion
Introduction
DNA Methylation Overview
Challenges & Solutions
The EpiTect Methyl II PCR Array System
Principle and Protocol
Research Applications
Pyrosequencing
Summary
4
Sample & Assay Technologies
5. Basic Gene Expression Model
Protein “A”
mRNA ”A”
Structural Gene “A”
5
Sample & Assay Technologies
6. The Current Model
Activated
Transcription Factors
RNAi:
shRNA
miRNA
Protein “A”
NFκB
+
p53
Transcription
Initiation Complex
mRNA ”A”
–
Histones
p53 BS Me
Me
Me
Me Me
NFκB BS
DNA Methylation
Histone-DNA
Interactions
Ac
Me
Me Me
Structural Gene “A”
or Reporter system
DNA Methylation
6
Sample & Assay Technologies
7. The Current Model
Activated
Transcription Factors
RNAi:
shRNA
miRNA
Protein “A”
NFκB
+
p53
Transcription
Initiation Complex
mRNA ”A”
–
Histones
p53 BS Me
Me
Me
Me Me
NFκB BS
DNA Methylation
Histone-DNA
Interactions
Ac
Me
Me Me
Structural Gene “A”
TSS (+1) or Reporter system
DNA Methylation
7
Sample & Assay Technologies
8. DNA Methylation: Introduction
NH2
N
O
N
H NH2
H
+DNMT
O
CH3
N S-Enz
AdoMet AdoHcy R
N
NH2
-DNMT
N
CH3
O
N
5-methyl-cytosine
cytosine
Stable, covalent DNA modification that
targets CpG dinucleotides
70%-80% of the CpG dinucleotides are
methylated in healthy mammalian cells
These methylated regions are typical of
the bulk chromatin that is relatively
inaccessible to transcription factors.
Associated with gene silencing
1
Normal
2
3
Expression
Promoter
Region
Cancer
Adapted from Herman,
J. and Baylin, S. N.
Engl. J. Med. 2003
1
2
3
No
Expression
CpG islands: CpG-rich regions in
human gene promoters
Promoter CpG islands are usually
unmethylated in normal tissues.
Exceptions include genes involved in
X-chromosome inactivation, gene
imprinting and tissue-specific
expression.
8
Sample & Assay Technologies
9. DNA Methylation and Transcriptional Repression
9
Blood, 93:4059-4070, 1999
Sample & Assay Technologies
10. Critical Biological Roles for DNA Methylation
Roles in normal development and disease progression
Potentially silences expression of critical tumor suppressors
Involves all cellular pathways
Methylated DNA can be detected in heterogenous fluids
Breast cancer: nipple aspirate
Lung cancer: bronchoalveolar lavage
Prostate cancer: urine
Multiple cancers: plasma and serum
DNA Methylation: Promising Biomarker
Early detection
Predicting prognosis
Mechanism of Action for Therapy Resistance/ Therapy Choice
10
Sample & Assay Technologies
11. Challenges in Existing Technologies
Current Workflow for DNA Methylation Analysis:
Commonly used pretreatment – sodium bisulfite conversion
Methods of analysis – Pyrosequencing, Methylation-specific PCR (MSP),
bisulfite sequencing, next-generation sequencing, MALDI-TOF MS, etc.
Benefits – Single-base resolution of methylome
Drawbacks – Protocol Optimization, laborious for many samples, need
for specialized equipment
WHY EpiTect Methyl II qPCR System?
Available for any laboratory with qPCR instrument
Complete System- Sample Isolation to DATA Analysis
Regional Methylation Pattern
More Biology - Less Time
Complimentary to Bisulfite Based Methods
11
Sample & Assay Technologies
12. Site Specific DNA Methylation Analysis
Using Bisulfite Treatment
m
G T C AG T G A CG
G T C AG T G A CG
Bisulfite Conversion
Bisulfite Conversion
G T U AG T G A CG
G T U AG T G A UG
PCR
G T T AG T G A CG
PCR
G T T AG T G A T G
12
Sample & Assay Technologies
13. Challenges in Existing Technologies
Current Workflow for DNA Methylation Analysis:
Commonly used pretreatment – sodium bisulfite conversion
Methods of analysis – Pyrosequencing, Methylation-specific PCR (MSP),
bisulfite sequencing, next-generation sequencing, MALDI-TOF MS, etc.
Benefits – Single-base resolution of methylome
Drawbacks – Protocol Optimization, laborious for many samples, need
for specialized equipment
WHY EpiTect Methyl II qPCR System?
Available for any laboratory with qPCR instrument
Complete System- Sample Isolation to DATA Analysis
Regional Methylation Pattern
More Biology - Less Time
Complimentary to Bisulfite Based Methods
13
Sample & Assay Technologies
14. Topics for Discussion
Introduction
DNA Methylation Overview
Challenges & Solutions
The EpiTect Methyl II PCR Array System
Principle and Protocol
Research Applications
Pyrosequencing
Summary
14
Sample & Assay Technologies
15. EpiTect DNA Methylation PCR System
Complete Solution from Sample Isolation through Data Analysis
DNA Isolation: QIAGEN Blood and Tissue Kit
EpiTect Methyl II DNA Restriction Kit
For fresh/frozen tissues and cells
EpiTect Methyl II PCR Arrays
96 or 384 well format compatible with most qPCR instruments
Cataloged - multiple assays (24 or 96) on one PCR Plate
Custom - available for every promoter in the human, mouse, and rat genome
EpiTect Methyl II PCR Assays
Primers for every promoter in the human, mouse, or rat genome with CpG island
EpiTect qPCR primer assay search portal
Optimized RT2 SYBR Green Master Mix
EpiTect Methyl II Data Analysis (Excel template)
15
Sample & Assay Technologies
16. DNA Methylation PCR Array Protocol Overview
(0.5 – 4 ug of
Genomic DNA)
16
Sample & Assay Technologies
17. DNA Methylation PCR Array Protocol Overview
Sample Preparation:
QIAGEN DNeasy Blood and Tissue Kit
17
Sample & Assay Technologies
18. DNA Methylation PCR Array Protocol Overview
(0.5 – 4 ug of
Genomic DNA)
18
Sample & Assay Technologies
19. How It Works:
Principle behind EpiTect Methyl II PCR Array
Based on the quantitative detection of remaining target DNA molecules
after treatment with a Methylation-sensitive (MSRE) and a Methylationdependent (MDRE) restriction enzyme mixtures.
Enzyme
How It Works
Remaining DNA
MOCK
No enzyme added
Input fraction
MSRE
Digests unmethylated and partially
methylated DNA copies
Methylated fraction
MDRE
Digests methylated and partially
methylated DNA copies
Unmethylated fraction
MSRE & MDRE
(Double)
Digests unmethylated, partially
methylated, and methylated DNA copies
Fraction resistant to enzyme digestion
(Analytical window)
19
Sample & Assay Technologies
20. DNA Methylation PCR Array Protocol Overview
(0.5 – 4 ug of
Genomic DNA)
20
Sample & Assay Technologies
21. DNA Methylation PCR Array Protocol Overview
(0.5 – 4 ug of
Genomic DNA)
Which EpiTect Methyl II
PCR Array do I use?
21
Sample & Assay Technologies
22. “Catalogued” EpiTect Methyl II PCR Arrays
Simultaneously analyze the DNA methylation status of 22- or 94-gene panels associated with
specific cancer types, other diseases or biological pathways.
96 and 384 well qPCR Arrays-Human and Mouse
Cancer Related
Pathway-Focused Methyl qPCR Arrays
Breast Cancer
Apoptosis
Epithelial to Mesenchymal
Transition
DNA Repair
Gastric Cancer
Inflammatory Response
Liver Cancer
T Cell Activation
Lung Cancer
Cytokine Production
Prostate Cancer
Tumor Suppressor Genes
Colon Cancer
Homeobox (HOX) Genes
Leukemia & Lymphoma
Polycomb (PcG) Genes
Tumor Suppressor Genes
Cell Cycle
Melanoma
Toll-Like Receptor Signaling
Cancer miRNAs
Stem Cell Transcription Factors
TGF-Beta/BMP Signaling
Wnt Signaling
Custom Arrays and Custom Assays Are Available
Available for most CpG island-containing promoter in the human, mouse, or rat genome.
22
http://www.sabiosciences.com/dna_methylation_custom_PCRarray.php
Sample & Assay Technologies
23. DNA Methylation PCR Array Protocol Overview
(0.5 – 4 ug of
Genomic DNA)
Data
Analysis
23
Sample & Assay Technologies
24. EpiTect Data Analysis
Excel Analysis Templates
Quickly Understand the Biology:
Results automatically calculated, analyzed,
and annotated
No Software to download, license or
install:
Simply paste in your raw Ct values
24
Sample & Assay Technologies
25. Advantages of the EpiTect Methyl II PCR System
Single Gene, Pathway or Disease-Focused Analysis
Screen large number of samples for few genes with single
assays
Simultaneously detect the methylation status of 22-94 genes
Compliments & validates genome-wide methylation studies
Fast, Reliable & Sensitive
Direct measurement of methylated & unmethylated DNA
Similar results and sensitivity as bisulfite sequencing, with no
bisulfite conversion
Higher throughput than bisulfite-PCR
Highly reproducible
Genome-Wide Coverage
Primers detecting methylation status of any human, mouse, or
rat gene with predicted CpG island
Bench-validated qPCR primers
25
Sample & Assay Technologies
27. EpiTect Methyl II PCR Array Principle:
Representational design
Sample 1
Sample 2
Unmethylated
1
Unmethylated
Hypermethylated
methylated
1
qPCR results
Each CpG Island is interrogated at multiple sites for both RE Digests
Unbiased qPCR since both primers are the same (valid ∆Ct calculations)
Internal Standard for each Assay (mock digest versus total digest)
Representational Design
Four selective methylation-specific digestion restriction
27
Sample & Assay Technologies
28. EpiTect Methyl II PCR Assays
Targets
Primers available for approximately 13,000 promoter CpG islands
Design includes CpG island or CpG dense areas associated with a transcription
start site (TSS)
CpG island & TSS definitions: UCSC Genome Bioinformatics Site & NCBI
Each assay corresponds to one distinct CpG island in a promoter region
EpiTect Methyl qPCR Assay Search Portal:
http://www.sabiosciences.com/dna_methylation_qPCRprimer.php
Amplicon Specifics
Selected from 5 kb upstream to 3 kb downstream of TSS
Each includes at least three or more of both MSRE and MDRE restriction sites
Size: 150 to 400 bp (240 bp average)
28
Sample & Assay Technologies
29. Laboratory QC Validation
of ALL EpiTect Methyl II PCR Assays & Arrays
All EpiTect Methyl II PCR Arrays and Assays are laboratory validated:
Assays in each PCR Array are tested for
Sensitivity:
Constant C(t) value for same amount of template
Amplification Efficiency:
Single curve analysis and standard curve dilutions
Specificity:
Single melt-peak during dissociation
Validation is done on every lot of primers and every EpiTect Methyl II PCR Array
Performance of all EpiTect Methyl II PCR Assays is guaranteed when used with
the RT2 SYBR-Green qPCR Mastermix
29
Sample & Assay Technologies
30. EpiTect Methyl qPCR Assay Efficiency
Amplification Efficiency
Amplification and Dissociation Curves
140%
PCR Efficiency
120%
100%
80%
60%
Mouse
40%
Human
20%
0%
0
100
200
300
400
500
Amplicon length in bp
Unique qPCR cycling Conditions (critical for assay performance)
Validated Primer Specificity & High Amplification Efficiency
Similar Amplification Efficiencies for Each Primer Pair
30
Sample & Assay Technologies
31. Melting Curve Analysis
Single Dissociation Peaks for Every Gene Assay
Example of QC criteria for
every PCR Assay
manufactured by
SABiosciences
Single peak dissociation
curves
Single gel bands of
predicted size
31
Sample & Assay Technologies
32. Melting Curve Analysis
Single Dissociation Peaks for Every Gene Assay
Example of QC criteria for
every PCR Assay
manufactured by
SABiosciences
Single peak dissociation
curves
Single gel bands of
predicted size
32
Sample & Assay Technologies
33. Melting Curve Analysis
Single Dissociation Peaks for Every Gene Assay
Example of QC criteria for
every PCR Assay
manufactured by
SABiosciences
Single peak dissociation
curves
Single gel bands of
predicted size
33
Sample & Assay Technologies
34. EpiTect Methyl II PCR Arrays
Comparable to Bisulfite Sequencing
CDH13
MCF7
MB231
HeLa
Unmethylated CpG sites
Methylated CpG sites
EpiTect Methyl II PCR Assays generated quantitative
methylation data comparable to bisulfite sequencing data.
34
Sample & Assay Technologies
35. EpiTect Methyl qPCR Assay Sensitivity
PERCENTAGE OF TOTAL INPUT DNA
SENSITIVITY COMPARABLE TO BISULFITE SEQUENCING
100.00%
90.00%
80.00%
70.00%
60.00%
50.00%
Unmethylated
40.00%
Methylated
30.00%
20.00%
10.00%
0.00%
100.0
75.0
50.0
33.3
12.5
6.3
PERCENT SKBR3 GENOMIC DNA (%)
0.0
Methylated tumor DNA detectable in heterogeneous samples containing
as little as 5% tumor.
35
Sample & Assay Technologies
36. EpiTect Methyl II PCR Arrays
Comparable to Illumina Infinium BeadChip
Comparison between 94 CpG sites (22 shown) important for breast cancers in MCF-7 cells
Similar results between 2 different platforms using different preparation methods
Methyl II PCR assays can be used to validate results from large scale screening projects
36
Sample & Assay Technologies
37. Topics for Discussion
Introduction
DNA Methylation Overview
Challenges & Solutions
The EpiTect Methyl II PCR Array System
Principle and Protocol
Research Applications
Pyrosequencing
Summary
37
Sample & Assay Technologies
38. Research Applications:
Methylation in Breast Cancer
Is there a difference in the Methylation status of breast cancer associated genes
among commonly used Breast Cancer Cell lines?
Obtained genomic DNA from Human Breast Cancer Cell lines (ATCC)
Normal Breast Tissue (Capital Bioscience)
EpiTect Methyl II Breast Cancer PCR Array
38
Sample & Assay Technologies
40. EpiTect Biomarker Discovery
Genomic DNA from 10 breast cancer, 1
prostate cancer cell line and normal
human breast tissue was isolated and
analyzed with the EpiTect Human Breast
Cancer Complete Panel PCR Array. The
heat map compares the methylation levels
of the 94 genes on the array.
CONCLUSION:
EpiTect Methyl II PCR Arrays
can be effectively used to
identify novel methylated
biomarkers.
40
Sample & Assay Technologies
41. EpiTect Biomarker Discovery
What’s next?
Verify gene expression
Using RT2 Profiler
PCR Arrays
Focus on individual
CpG sites by
pyrosequencing
41
Sample & Assay Technologies
42. Topics for Discussion
Introduction
DNA Methylation Overview
Challenges & Solutions
The EpiTect Methyl II PCR Array System
Principle and Protocol
Research Applications
Pyrosequencing
Summary
42
Sample & Assay Technologies
43. Site Specific DNA Methylation Analysis
Using Bisulfite Treatment
Importance
m
GG T C AG T G A CG
Crucial step to analyze CpG methylation
Required to distinguish between methylated and
Bisulfite Conversion
GG T U AG T G A CG
PCR
unmethylated cytosines
GG T T AG T G A CG
GG T C AG T G A CG
Bisulfite Conversion
GG T U AG T G A UG
Cells
Blood
PCR
Bisulfite treatment
converts
unmethylated
C into U
gDNA
Converted
DNA
GG T T AG T G A T G
Analysis
Biopsies
Paraffin
slides
43
Sample & Assay Technologies
44. The Principle of Pyrosequencing Technology
Workflow
~ 2h
Assay Design
PCR
Region of interest
amplified with a
biotinylated primer
~ 15 min
Sample prep
~ 10-60 min
Pyrosequencing
Separation to single
stranded DNA using
streptavidin-coated
beads.
Sequencing-by-synthesis.
Sequence data generated
from the first base next to
the sequencing primer.
Annealing of sequencing
primer.
Sequence context as built in
control
44
Sample & Assay Technologies
45. Instrument overview
Software functionality and application areas
PyroMark Q24
PyroMark Q96 ID
PyroMark Q96 MD
PyroMark Q96 MD
Automated
Throughput
1–24 samples
1–96 samples
1–96 samples
10–960 with automation
option
Running volume
25 µl
40 µl
12 µl
12 µl
PCR
requirements
10–20 µl
(~1-3 pmol of product)
20–40 µl
(2-4 pmol of product)
5–10 µl
(0.5-1.5 pmol of product)
5–10 µl
(0.5-1.5 pmol of product)
Read lengths
(estimates)
SQA
SNP
AQ
CpG
SQA
SNP
AQ
CpG
SNP
AQ
CpG
SNP
AQ
CpG
Main
applications
Genetic testing
Epigenetics
Microbilogy
Genetic testing
Epigenetics
Microbiology
Epigenetics
Genetic testing
Epigenetics
Genetic testing
(SNP/AQ only in batch
mode)
Sensitivity
5% mutation
95% wt
10% mutation
90% wt
2% mutation
98% wt
2% mutation
98% wt
~50 – 100 bp
~10 – 100 bp
~10 – 100 bp
~10 – 120 bp
~40 – 70 bp
~10 – 100 bp
~10 – 100 bp
~10 – 120 bp
~10 – 100 bp
~10 – 100 bp
~10 – 140 bp
~10 – 100 bp
~10 – 100 bp
~10 – 140 bp
45
** Additional Software (SW) (PyroMark CpG SW) needed on ID and MD instruments
Sample & Assay Technologies
46. Pyrosequencing for DNA Methylation Analysis
PyroMark CpG Assays – Release Information
PyroMark CpG Assays
PyroMark CpG Assays
Pre-designed
DNA-methylation assays
Human
Number of assays: over 30,000
Number of CpG Islands with assay: ~12,000
(~80%)
Mouse
Number of assays: over 30,000
Number of CpG Islands with assay: ~11,000
(<80%)
46
Sample & Assay Technologies
47. Pyrosequencing Workflow
PCR
Can Use Any PCR Machine / PCR Reagents / Compatible with Q-PCR
Amplify relevant region by PCR (60 - 1000 bp)
Can Use Very Short PCR Products if Desired (i.e. Degraded DNA)
One primer is biotinylated
PCR primer
Region of interest
PCR primer
biotinylated
47
Sample & Assay Technologies
48. Pyrosequencing Workflow
Sample preparation
Assay Design
PCR
Sample prep
Pyrosequencing
Immobilize biotinylated PCR
products onto streptavidin coated beads
Separate strands by denaturation in NaOH
Wash/neutralize the immobilized strand
Anneal sequencing primer
48
Sample & Assay Technologies
49. Pyrosequencing for DNA Methylation Analysis
Analyzing a Pyrogram for DNA-methylation
Sequence to be analyzed:
•
AGTTAC GAC
m
•
After bisulfite
conversion:
AG T TAC GAC•
and A G T T A C G A C
•
•
AG TTATGAT •
and A G T T A C G A T
•
Biotinylated PCR strand:
49
Sample & Assay Technologies
50. Pyrosequencing for DNA Methylation Analysis
Analyzing a Pyrogram for DNA-methylation
Sequence to be analyzed:
•
AGTTAC GAC
m
•
After bisulfite
conversion:
AG T TAC GAC•
and A G T T A C G A C
•
•
AG TTATGAT •
and A G T T A C G A T
•
Biotinylated PCR strand:
Analyzed sequence:
CpG methylation level:
50
Sample & Assay Technologies
51. Pyrosequencing for DNA Methylation Analysis
A Range of Analysis Possibilities
Any single CpG site
A4: TAYGGTTTGTA
57%
200
150
100
50
0
E
S
A
T
G
A
T
C
G
T
G
5
Multiple consecutive CpG sites
B 7 : Y G G T A T G T G G A T A T T T T Y G Y G T G G G T A T T T T T AYGGGGAT AT T T T GGT T AT YGT YGYGYGGAT AT T T T T AYGAGGAT AT T T YGGT YGYGYGGAT AT T T AT YGYGGGGAY
37%
35%
36%
33%
33%
32%
33%
30%
31%
38%
37%
29%
36%
30%
31%
34%
34%
2000
1500
1000
500
0
E S A TCGT A TGTGA TCGA T TC TG TCGTGTA TC TGA TC GGA TA T TGTCGA TCA GTC TGTCAGTCGA T A TC TGA TCGAGA TGA T TC TGTCAGTC TGT CGA TA TCGA TCAGTC GGTA TCAGT TCGA T
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
One gene at a time
Several genes in the same analysis (analyze up to 96 different assays in one run)
Global methylation level
Estimate the global methylation levels using repetitive elements
51
Sample & Assay Technologies
52. Topics for Discussion
Introduction
DNA Methylation Overview
Challenges & Solutions
The EpiTect Methyl II PCR Array System
Principle and Protocol
Research Applications
Pyrosequencing
Summary
52
Sample & Assay Technologies
53. DNA Methylation Analysis at QIAGEN
Complete Solution from Sample Isolation through Data Analysis
DNA Methylation is a promising biomarker and is important in regulating
gene expression through several mechanisms
DNA Methylation can be identified using simple restriction digests on a
regional basis using the EpiTect Methyl II PCR Array System
Complete system from DNA isolation through data analysis
DNA Methylation can be identified on site-by-site basis using EpiTect
pyrosequencing
Simple, easy to use system with predesigned assays
53
Sample & Assay Technologies
54. EpiTect Methyl II PCR System
Pilot Project Starter Offer:
2 Free EpiTect Methyl II Signature Panels or 2 Free EpiTect
Methyl II Assays
With purchase of:
DNA RE Kit
SYBR Green MasterMix
Call 1-888-503-3187
Use Code: FDK-MTFAS22
Outside US and Canada?
Request demo QIAwebinars@QIAGEN.com
54
Sample & Assay Technologies
55. EpiTect Methyl II Pilot Study
96 and 384 well qPCR Arrays-Human and Mouse
Cancer Related
Pathway-Focused Methyl qPCR Arrays
Breast Cancer
Apoptosis
Epithelial to Mesenchymal
Transition
DNA Repair
Gastric Cancer
Inflammatory Response
Liver Cancer
T Cell Activation
Lung Cancer
Cytokine Production
Prostate Cancer
Tumor Suppressor Genes
Colon Cancer
Homeobox (HOX) Genes
Leukemia & Lymphoma
Polycomb (PcG) Genes
Tumor Suppressor Genes
Cell Cycle
Melanoma
Toll-Like Receptor Signaling
Cancer miRNAs
Stem Cell Transcription Factors
TGF-Beta/BMP Signaling
Wnt Signaling
55
Sample & Assay Technologies
56. EpiTect Methyl qPCR System
Questions, Comments, Concerns?
US Applications Support
888-503-3187
support@sabiosciences.com
̣
Questions, Comments, Concerns?
Global Applications Support
SAB.EU@qiagen.com
The EpiTect Methyl qPCR Arrays and Assays are intended for molecular biology applications.
This product is not intended for diagnosis, prevention, or treatment of disease.
56
Sample & Assay Technologies